Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540058 | 0.90 | ERN1 (0.35) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL27760976 | 0.89 | NR3C1 (0.35) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL5774836 | 0.87 | NR3C1 (0.43) | NR3C2NR3C1 | |
| SCHEMBL1260203 | 0.84 | L3MBTL1 (0.42) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL1261086 | 0.82 | CTSS (0.32) | KMT2AMEN1CA1CA2 | |
| SCHEMBL3751137 | 0.82 | CTSS (0.32) | KMT2AMEN1CA1CA2 | |
| SCHEMBL1261398 | 0.81 | HSD11B1 (0.33) | PDK1PDK2PDK3PDK4SMN1; SMN2 | |
| SCHEMBL27782548 | 0.77 | L3MBTL1 (0.36) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL27782520 | 0.76 | P2RX7 (0.34) | PDK1PDK2PDK3PDK4L3MBTL1 | |
| SCHEMBL27782566 | 0.76 | TLR2 (0.33) | PDK1PDK2PDK3PDK4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994005-B9 | TETRAHYDRONAPHTHALINE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | Bayer Pharma AG (DE) | 2012-01-11 | — | — | EP | disclosed |
| EP-1994005-B1 | TETRAHYDRONAPHTHALINE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-7880042-B2 | antiinflammatory agents; (5 alpha ,6 alpha ,8 beta )-2-fluoro-8-methyl-5-[(2-methylquinoline-5-yl)amino]-6-(trifluoromethyl)-5,6,7,8-tetrahydronaphthalene-1,6-diol; side effect reduction | BAYER SCHERING PHARMA AG (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20100298311-A1 | TETRAHYDRONAPHTHALENE DERIVATES, PROCESS FOR PREPARING THEM AND THEIR USE AS ANTIINFLAMMATORY AGENTS | BERGER MARKUS | 2010-11-25 | — | — | US | disclosed |
| EP-1994005-A1 | TETRAHYDRONAPHTHALINE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-11-26 | — | — | EP | disclosed |
| US-20070225290-A1 | Tetrahydronaphthalene derivates, processes for preparing them and their use as antiinflammatory agents | BAYER SCHERING PHARMA AG (DE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007104582-A1 | TETRAHYDRONAPHTHALINE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225290-A1 | Tetrahydronaphthalene derivates, processes for preparing them and their use as antiinflammatory agents | TNF, IL1B, DHPS | PDK1 2607/4885PDK2 1328/4885PDK3 1936/4885 |
| US-20100298311-A1 | TETRAHYDRONAPHTHALENE DERIVATES, PROCESS FOR PREPARING THEM AND THEIR USE AS ANTIINFLAMMATORY AGENTS | TNF, IL1B, DHPS | PDK1 2663/4885PDK2 1448/4885PDK3 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.